ES8706717A1 - Metodo de preparar esteroides - Google Patents

Metodo de preparar esteroides

Info

Publication number
ES8706717A1
ES8706717A1 ES535643A ES535643A ES8706717A1 ES 8706717 A1 ES8706717 A1 ES 8706717A1 ES 535643 A ES535643 A ES 535643A ES 535643 A ES535643 A ES 535643A ES 8706717 A1 ES8706717 A1 ES 8706717A1
Authority
ES
Spain
Prior art keywords
steroids
containing same
compositions containing
therapeutic compositions
hyperglycemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES535643A
Other languages
English (en)
Other versions
ES535643A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of ES8706717A1 publication Critical patent/ES8706717A1/es
Publication of ES535643A0 publication Critical patent/ES535643A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO DE PREPARAR ESTEROIDES. CONSISTE EN PROTEGER LOS GRUPOS REACTIVOS DEL MATERIAL DE PARTIDA, EFECTUAR REACCIONES DE SUSTITUCION DE ANILLO EN UN DISOLVENTE ORGANICO A PRESION ATMOSFERICA Y A UNA TEMPERATURA ENTRE -80GC Y LA DE REFLUJO DE LA MEZCLA DE REACCION, Y ELIMINAR CUALESQUIERA GRUPOS PROTECTORES OPCIONALMENTE AÑADIDOS, PARA PRODUCIR ESTEROIDES DE FORMULA (I) DONDE R1, R2, R3, R4, R5, R6, R7 Y R8 SE ELIGEN CADA UNO DEL GRUPO FORMADO POR HIDROGENO, ALQUILO, ALQUENILO, HALOGENO E HIDROXILO; Y N ES UN ENTERO DE 1 A 2. TIENEN APLICACIONES FARMACEUTICAS COMO AGENTES ANTICANCER Y ANTIOBESIDAD. *FORMULA*
ES535643A 1983-08-02 1984-08-02 Metodo de preparar esteroides Expired ES8706717A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51955083A 1983-08-02 1983-08-02

Publications (2)

Publication Number Publication Date
ES8706717A1 true ES8706717A1 (es) 1987-07-01
ES535643A0 ES535643A0 (es) 1987-07-01

Family

ID=24068794

Family Applications (1)

Application Number Title Priority Date Filing Date
ES535643A Expired ES8706717A1 (es) 1983-08-02 1984-08-02 Metodo de preparar esteroides

Country Status (10)

Country Link
EP (2) EP0423842A3 (es)
JP (1) JPS6069096A (es)
AU (1) AU582122B2 (es)
CA (1) CA1314870C (es)
DE (1) DE3485647D1 (es)
DK (1) DK375384A (es)
ES (1) ES8706717A1 (es)
GR (1) GR80020B (es)
IE (1) IE72193B1 (es)
IL (1) IL72566A (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804576A (en) * 1983-08-02 1998-09-08 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17-ones and 5-androstan-17-ones
US5714481A (en) * 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US5656621A (en) * 1983-08-02 1997-08-12 Research Corporation Tech., Inc. Steroids useful as anti-cancer and anti-obesity agents
US5157031A (en) * 1983-08-02 1992-10-20 Research Corporation Technologies, Inc. Method for prophylaxis of obesity
CA1314871C (en) * 1985-08-02 1993-03-23 Arthur G. Schwartz Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hypercholesterolemic agents
AU601184B2 (en) * 1986-05-21 1990-09-06 Research Corporation Steroids useful as anti-cancer and anti-obesity agents
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
JPS63267722A (ja) * 1987-04-27 1988-11-04 Daiichi Yakuhin Sangyo Kk 抗肥満症剤
US4897390A (en) * 1987-07-21 1990-01-30 Ruhe Rodney C Novel anti-obesity compounds and method of use
JPS6440428A (en) * 1987-08-07 1989-02-10 Daiichi Yakuhin Sangyo Kk Antihyperlipemia
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
US5028631A (en) * 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US5175154A (en) * 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
AU652130B2 (en) * 1989-09-25 1994-08-18 University Of Utah Research Foundation Use of steroid hormones in compositions for inducing T cell lymphokine production
US5753237A (en) * 1989-09-25 1998-05-19 University Of Utah Research Foundation Method for augmenting immunological responses
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
CA2090759A1 (en) * 1990-08-29 1992-03-01 Henry A. Lardy Treatment process for promoting weight loss employing a substituted 5-androstene
US5506223A (en) * 1990-08-29 1996-04-09 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
JPH0684398B2 (ja) * 1990-08-31 1994-10-26 雪印乳業株式会社 新規なアンドロステン誘導体及びそれを用いる６‐アルキルカルボニルオキシ‐１４α‐ヒドロキシ‐アンドロスト‐４，６‐ジエン‐３，１７‐ジオンの製造法
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
BR0009476A (pt) * 1999-03-23 2002-02-19 Hollis Eden Pharmaceuticals Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
EP1422234A3 (en) * 1999-03-23 2010-12-08 Harbor BioSciences, Inc. Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
WO2001023405A2 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
WO2011138460A1 (en) * 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof
CA2913192A1 (en) 2013-05-21 2014-11-27 Dr. Reddy's Laboratories Limited Processes for the preparation of dehydroepiandrosterone and its intermediates
CA2953917C (en) * 2013-07-01 2021-10-19 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
CA2986319A1 (en) 2014-06-17 2015-12-23 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
EP3805243B1 (en) * 2019-10-09 2023-11-15 Windtree Therapeutics, Inc. Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833793A (en) * 1957-09-30 1958-05-06 Searle & Co 17-oxygenated derivatives of 5-androstene-1, 3-diol
US2911418A (en) * 1959-01-02 1959-11-03 Searle & Co 16-halo 17-oxygenated androst-5-en-3-ols and esters
FR1355505A (fr) * 1959-02-03 1964-03-20 Upjohn Co Procédé de préparation de 6-fluoro stéroïdes de la série de l'androstène
GB876009A (en) * 1959-11-26 1961-08-30 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3148198A (en) * 1960-09-06 1964-09-08 Searle & Co 3, 17-bisoxygenated 16alpha, 16beta-difluoroandrostenes and process
US3018298A (en) * 1961-03-14 1962-01-23 Searle & Co 17-oxygenated 3alpha-halo-5alpha-androstan-2beta-ols and derivatives thereof
GB989503A (en) * 1962-08-29 1965-04-22 British Drug Houses Ltd 6,16-disubstituted androstenes and process for the preparation thereof
DE1239306B (de) * 1963-05-11 1967-04-27 Vismara Francesco Spa Verfahren zur Herstellung von Ketosteroiden, die in alpha-Stellung zur Ketogruppe eine gegebenenfalls substituierte Allylgruppe tragen
US3166578A (en) * 1963-11-12 1965-01-19 Searle & Co (optionally 17-alkylated) 17-oxygenated 5alpha-androst-2-en-4-ones and intermediatesthereto
BE666194A (es) * 1964-06-30
US3357888A (en) * 1965-04-07 1967-12-12 Upjohn Co 4, 7-dimethyl androstene derivatives
BE754111A (fr) * 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
JPS5031155B2 (es) * 1972-05-29 1975-10-07
US3976691A (en) * 1972-12-11 1976-08-24 E. I. Du Pont De Nemours And Company Dialkylaminosulfur trifluorides as fluorinating agents
GB1550343A (en) * 1975-07-16 1979-08-15 Gist Brocades Nv Androstane derivatives
DE2705917C3 (de) * 1977-02-09 1980-05-08 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 3 ß , 16 ß -Dihydroxy-5-androsten- 17-on durch mikrobiologische Hydrolyse
DE2757157C3 (de) * 1977-12-19 1980-10-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 16 a -alkylierten Steroiden
EP0014971B1 (de) * 1979-02-16 1982-06-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-alpha-Hydroxydehydroepiandrosteron
IE53463B1 (en) * 1981-06-15 1988-11-23 Akzo Nv Mono-and bisquaternary ammonium derivatives of 2 beta,16 beta-d-amino-5 alpha-androstane derivatives and pharmaceutical preparations containing same

Also Published As

Publication number Publication date
EP0133995A3 (en) 1985-11-27
AU582122B2 (en) 1989-03-16
ES535643A0 (es) 1987-07-01
AU3145684A (en) 1985-10-03
IL72566A (en) 1988-08-31
DK375384D0 (da) 1984-08-02
CA1314870C (en) 1993-03-23
GR80020B (en) 1984-12-11
EP0133995B1 (en) 1992-04-15
EP0423842A3 (en) 1991-08-07
JPS6069096A (ja) 1985-04-19
DK375384A (da) 1985-02-03
EP0423842A2 (en) 1991-04-24
DE3485647D1 (de) 1992-05-21
IE841991L (en) 1985-02-02
IL72566A0 (en) 1984-11-30
EP0133995A2 (en) 1985-03-13
IE72193B1 (en) 1997-03-26

Similar Documents

Publication Publication Date Title
ES8706717A1 (es) Metodo de preparar esteroides
IL67920A0 (en) New derivatives of 3-keto delta 4,9,19-nor steroids,their preparation,their application as medicaments,the compositions containing them and the new intermediates obtained
IE830227L (en) Pyrazolooxazines
AU569086B2 (en) 2-pyrimidinyl-1-piperazine derivatives
DE3478114D1 (en) Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside
TW229208B (es)
TR199901578T2 (xx) Klaritromisin form 0 kristali
ES8600737A1 (es) Procedimiento de preparar compuestos de sulfonio
MY103850A (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them.
MY116845A (en) New 19-nor-pregnene derivatives
ES8502105A1 (es) Un procedimiento para la preparacion de derivados de diben- zopirano
GR850472B (es)
ES2000613A6 (es) Metodo de preparar nuevos esteroides
SE8405588D0 (sv) New compounds
ES8604520A1 (es) Procedimiento para preparar derivados de 2(1h)-piridona
ES8206455A1 (es) Procedimiento para la preparacion de derivados de guanidina
AU7329687A (en) Steroids useful as anti-cancer and anti-obesity agents
IL111791A0 (en) Glutaramide derivatives
ES8602676A1 (es) Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina.
ES8504799A1 (es) Procedimiento de obtencion de piridopirimidinonas
ES8802233A1 (es) Un procedimiento para la preparacion de nuevos 11-metileno-esteroides.
ES2027507A6 (es) Procedimiento de preparacion de derivados selenofenicos.
ES8500928A1 (es) Procedimiento para la obtencion de oxaspirododecan-derivados de efecto perfumante
ES8407047A1 (es) Un procedimiento para la preparacion de un compuesto de 5-aril-1,2,3,4-tetrahidro-y-carbolina-2-sustituida.
ES8107003A1 (es) Procedimiento pra la preparacion de nuevas benzamidas susti-tuidas

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040414